Efficacy and safety of obinutuzumab β in patients with active systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Rheumatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles